2 completed, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 5 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Withdrawn 2, Not yet recruiting 1 |
| Not applicable | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Yttrium-90 Microsphere Radioembolization: new trials by email Literature Review of Yttrium-90 Microsphere Radioembolization trials Research Report on Yttrium-90 Microsphere Radioembolization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma Angiography, Biopsy, Biospecimen Collection - Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Recruiting | Mayo Clinic | 16 | 2024-06-06 | 2026-05-13 |
| Y-90 Versus SBRT for Inoperable HCC Quality of Life, Questionnaire Administration, Stereotactic Body Radiation Therapy - Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8 | Phase 2 | Withdrawn | OHSU Knight Cancer Institute | 2023-12-01 | 2023-03-23 | |
| Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy Y-90 SIR-Spheres, Yttrium-90 Microsphere Radioembolization, Systemic Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Withdrawn | Emory University | 2022-08-17 | 2024-01-19 | |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) Computed Tomography, Hepatobiliary Iminodiacetic Acid Scan, Single Photon Emission Computed Tomography - Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2019-10-10 | 2026-05-22 |
| Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases Arterial Embolization, Pembrolizumab, Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate - Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm | Phase 2 | Completed | Nicholas Fidelman, MD | 32 | 2018-08-27 | 2026-08-28 |
| Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging - Hepatocellular Carcinoma | Phase 2 | Completed | Thomas Jefferson University | 104 | 2017-07-01 | 2026-01-02 |
Carcinoma, Hepatocellular (4) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Neuroendocrine Tumors (1)
OHSU Knight Cancer Institute (2) · Emory University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Nicholas Fidelman, MD (1) · Thomas Jefferson University (1)
United States (6)
Adel Kardosh (1) · Armeen Mahvash (1) · John Eisenbrey, PhD (1) · Nicholas Fidelman, MD (1) · Nima Kokabi (1) · Nima Nabavizadeh (1) · Umair Majeed, MD (1)
P30CA016672 (1), P30CA138292 (1), R01CA238241 (1)